JP2015521050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521050A5 JP2015521050A5 JP2015515598A JP2015515598A JP2015521050A5 JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5 JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5
- Authority
- JP
- Japan
- Prior art keywords
- maf
- subject
- expression level
- copy number
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039189 Transcription factor Maf Human genes 0.000 claims 39
- 230000014509 gene expression Effects 0.000 claims 26
- 238000000034 method Methods 0.000 claims 20
- 206010027476 Metastases Diseases 0.000 claims 16
- 230000009401 metastasis Effects 0.000 claims 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 15
- 201000005202 lung cancer Diseases 0.000 claims 15
- 208000020816 lung neoplasm Diseases 0.000 claims 15
- 239000000523 sample Substances 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 13
- 102000014128 RANK Ligand Human genes 0.000 claims 12
- 108010025832 RANK Ligand Proteins 0.000 claims 12
- 210000000988 bone and bone Anatomy 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 229940122361 Bisphosphonate Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 150000004663 bisphosphonates Chemical class 0.000 claims 6
- 230000015556 catabolic process Effects 0.000 claims 6
- 238000006731 degradation reaction Methods 0.000 claims 6
- 239000013068 control sample Substances 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 230000003321 amplification Effects 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 102000055006 Calcitonin Human genes 0.000 claims 3
- 108060001064 Calcitonin Proteins 0.000 claims 3
- 102000004171 Cathepsin K Human genes 0.000 claims 3
- 108090000625 Cathepsin K Proteins 0.000 claims 3
- 108020004635 Complementary DNA Proteins 0.000 claims 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims 3
- 102000008108 Osteoprotegerin Human genes 0.000 claims 3
- 108010035042 Osteoprotegerin Proteins 0.000 claims 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims 3
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 238000010804 cDNA synthesis Methods 0.000 claims 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 3
- 229960004015 calcitonin Drugs 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 229960001251 denosumab Drugs 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 229940079488 strontium ranelate Drugs 0.000 claims 3
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 3
- 229960004276 zoledronic acid Drugs 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- -1 EGFR inhibitors Chemical compound 0.000 claims 2
- 101001068638 Homo sapiens Basic salivary proline-rich protein 3 Proteins 0.000 claims 2
- 101000879840 Homo sapiens Serglycin Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 229940121647 egfr inhibitor Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007850 in situ PCR Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000011337 individualized treatment Methods 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656372P | 2012-06-06 | 2012-06-06 | |
| US61/656,372 | 2012-06-06 | ||
| PCT/IB2013/001859 WO2013182912A2 (en) | 2012-06-06 | 2013-06-06 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521050A JP2015521050A (ja) | 2015-07-27 |
| JP2015521050A5 true JP2015521050A5 (OSRAM) | 2016-08-04 |
| JP6386450B2 JP6386450B2 (ja) | 2018-09-05 |
Family
ID=49237517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515598A Active JP6386450B2 (ja) | 2012-06-06 | 2013-06-06 | 肺がん転移の診断、予後診断および処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10006091B2 (OSRAM) |
| EP (2) | EP2859120B1 (OSRAM) |
| JP (1) | JP6386450B2 (OSRAM) |
| KR (1) | KR102226219B1 (OSRAM) |
| CN (1) | CN104603288B (OSRAM) |
| AU (2) | AU2013273242B2 (OSRAM) |
| BR (1) | BR112014030750A2 (OSRAM) |
| CA (1) | CA2875918A1 (OSRAM) |
| DK (1) | DK2859120T3 (OSRAM) |
| ES (1) | ES2705237T3 (OSRAM) |
| MX (1) | MX368513B (OSRAM) |
| TR (1) | TR201819859T4 (OSRAM) |
| WO (1) | WO2013182912A2 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3091085B1 (en) | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20140105918A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| CA2906394A1 (en) * | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) * | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| CA2987389A1 (en) * | 2014-06-02 | 2015-12-10 | Valley Health System | Method and systems for lung cancer diagnosis |
| CN104398506A (zh) * | 2014-12-09 | 2015-03-11 | 厦门大学 | 雷奈酸锶在制备预防和治疗腺癌药物中的新用途 |
| CA2967224C (en) * | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| RU2017135072A (ru) | 2015-03-12 | 2019-04-10 | Мори Матрикс, Инк. | Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| CN105154542B (zh) * | 2015-09-01 | 2018-04-17 | 杭州源清生物科技有限公司 | 一组用于肺癌分子分型的基因及其应用 |
| JP7080819B2 (ja) * | 2016-02-25 | 2022-06-06 | セル メディカ スイッツァランド アーゲー | Ｐｄ－ｌ１に対する結合メンバー |
| WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
| DK3458610T3 (da) | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
| CN106055921A (zh) * | 2016-05-27 | 2016-10-26 | 华中农业大学 | 基于基因表达和药物靶标的药物活性预测与筛选方法 |
| CN106119405B (zh) * | 2016-08-31 | 2019-11-12 | 广州万德基因医学科技有限公司 | 一种肺癌的预后标记物、使用该标记预测肺癌预后的方法及应用 |
| CN107058480B (zh) * | 2016-12-14 | 2018-07-13 | 河北医科大学第四医院（河北省肿瘤医院） | 用于诊断肺腺癌的长链非编码rna标志物 |
| CN106815486B (zh) * | 2017-01-22 | 2021-06-04 | 华中农业大学 | 一种个性化用药的系统药理学方法 |
| CN107058499B (zh) * | 2017-01-25 | 2020-03-13 | 河北医科大学第四医院（河北省肿瘤医院） | 一种用于肺腺癌诊治的分子标志物 |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| WO2019152788A1 (en) | 2018-02-02 | 2019-08-08 | Morgan And Mendel Genomics, Inc. | Robust genomic predictor of breast and lung cancer metastasis |
| KR102218199B1 (ko) | 2019-01-31 | 2021-02-22 | 중앙대학교 산학협력단 | 폐암 전이 예측용 바이오마커 조성물 |
| CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
| CN110093422A (zh) * | 2019-05-24 | 2019-08-06 | 中国人民解放军西部战区总医院 | Linc02159在肺腺癌诊疗中的应用 |
| KR102260915B1 (ko) * | 2020-02-19 | 2021-06-04 | 한국원자력의학원 | 폐암의 방사선 치료 예후 예측을 위한 생체 표지자 |
| CN119143798B (zh) * | 2024-08-01 | 2025-09-30 | 河北医科大学 | 一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用 |
| CN119876392B (zh) * | 2025-01-06 | 2025-08-12 | 上海市第六人民医院 | 一种用于辅助诊断肺腺癌骨转移的生物标志物 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3688418T2 (de) | 1985-02-13 | 1993-08-26 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| DE951551T1 (de) | 1996-12-23 | 2000-09-14 | Immunex Corp., Seattle | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| HK1039108A1 (zh) | 1999-03-15 | 2002-04-12 | Axys Pharmaceuticals, Inc. | 以n-氰甲基酰胺作为蛋白酶抑制剂 |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| JP2003525874A (ja) | 2000-01-06 | 2003-09-02 | メルク フロスト カナダ アンド カンパニー | プロテアーゼ阻害剤としての新規化合物および組成物 |
| US7214781B2 (en) | 2000-06-21 | 2007-05-08 | Hitachi Chemical Research Center, Inc. | Gene markers for lung cancer |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1730308A4 (en) | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| EP1941050B1 (en) | 2005-09-20 | 2017-04-26 | Janssen Diagnostics, LLC | Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes |
| EP1931994A2 (en) * | 2005-09-26 | 2008-06-18 | Novartis AG | Molecular markers associated with bone metastasis |
| CA2632451C (en) | 2005-12-06 | 2015-11-03 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| EP2152316A4 (en) * | 2007-04-26 | 2011-03-23 | Quark Pharmaceuticals Inc | THERAPEUTIC DELIVERY OF INHIBITORY NUCLEIC ACID MOLECULES IN THE RESPIRATORY SYSTEM |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| CA2702805A1 (en) | 2007-10-18 | 2009-04-23 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| CN102123708A (zh) | 2008-06-06 | 2011-07-13 | 大学健康网络 | 用于治疗恶性血液疾病的8-羟基喹啉衍生物 |
| EP2297360A1 (en) * | 2008-07-02 | 2011-03-23 | Assistance Publique - Hôpitaux de Paris | A method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| EP3091085B1 (en) | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| US20140162887A1 (en) | 2011-02-04 | 2014-06-12 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US20140105918A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| CA2906394A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| MX362041B (es) | 2013-10-09 | 2019-01-07 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
| DK3158057T3 (da) | 2014-06-17 | 2019-07-29 | Igenomix S L | Stamcelleterapi ved endometriepatologier |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3458610T3 (da) | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
-
2013
- 2013-06-06 BR BR112014030750A patent/BR112014030750A2/pt not_active Application Discontinuation
- 2013-06-06 WO PCT/IB2013/001859 patent/WO2013182912A2/en not_active Ceased
- 2013-06-06 KR KR1020147035982A patent/KR102226219B1/ko active Active
- 2013-06-06 MX MX2014014802A patent/MX368513B/es active IP Right Grant
- 2013-06-06 DK DK13766663.2T patent/DK2859120T3/en active
- 2013-06-06 TR TR2018/19859T patent/TR201819859T4/tr unknown
- 2013-06-06 US US14/405,724 patent/US10006091B2/en active Active
- 2013-06-06 CN CN201380037529.4A patent/CN104603288B/zh active Active
- 2013-06-06 EP EP13766663.2A patent/EP2859120B1/en active Active
- 2013-06-06 EP EP18206025.1A patent/EP3467124A1/en not_active Withdrawn
- 2013-06-06 ES ES13766663T patent/ES2705237T3/es active Active
- 2013-06-06 JP JP2015515598A patent/JP6386450B2/ja active Active
- 2013-06-06 AU AU2013273242A patent/AU2013273242B2/en active Active
- 2013-06-06 CA CA2875918A patent/CA2875918A1/en not_active Abandoned
-
2018
- 2018-05-21 US US15/984,629 patent/US11352673B2/en active Active
-
2019
- 2019-06-18 AU AU2019204269A patent/AU2019204269A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521050A5 (OSRAM) | ||
| JP2016516403A5 (OSRAM) | ||
| Thomas et al. | Expression profiling of cervical cancers in I ndian women at different stages to identify gene signatures during progression of the disease | |
| Han et al. | MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1 | |
| JP2015520606A5 (OSRAM) | ||
| Pichler et al. | miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor | |
| Shames et al. | High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck | |
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| JP2016105731A5 (OSRAM) | ||
| JP5690588B2 (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| Hung et al. | Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma | |
| JP2013541339A5 (OSRAM) | ||
| JP6039656B2 (ja) | 癌再発の予後予測のための方法および装置 | |
| Shen et al. | microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation | |
| CN105980576B (zh) | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 | |
| JP2019523641A5 (OSRAM) | ||
| Lin et al. | Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway | |
| JP2010535473A5 (OSRAM) | ||
| JP6931926B2 (ja) | 遺伝子発現プロファイル及び乳癌におけるその使用 | |
| Davidson et al. | Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions | |
| JP2008536480A5 (OSRAM) | ||
| EP3215635A1 (en) | Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis | |
| JP2014533960A5 (OSRAM) | ||
| Pan et al. | miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma | |
| Puente et al. | Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma |